Citius Oncology, Inc.
HealthcareNASDAQ:CTOR · NASDAQ Global Market
-$0.03 today
Vol 0.04M · Avg 0.14M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.2%
avg -45.2%
ROIC
-45.7%
avg -39.3%
ROA
-24.5%
avg -25.4%
Analysis
ROA is currently the strongest return metric at -24.5% versus its period average of -25.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Myron Z. Holubiak | Executive Vice Chairman & Secretary | $450,000.00 | — | 79 | $850,000.00 | 0.91% |
Myron S. Czuczman | Executive Vice President & Chief Medical Officer | $225,000.00 | — | 66 | $850,000.00 | 0.91% |
Leonard L. Mazur | Chief Executive Officer, President & Executive Chairman | $166,250.00 | — | 81 | $1.70M | 1.83% |
Jaime Bartushak | Chief Financial Officer & Treasurer | — | — | 58 | $825,000.00 | 0.89% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Owlet, Inc.
NYSE:OWLT
$84.14M
Scilex Holding Company
NASDAQ:SCLX
$72.18M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages CTOR?
Citius Oncology, Inc. (CTOR) lists 4 active executives. The top listed executive is Myron S. Czuczman, Executive Vice President & Chief Medical Officer.
Are CTOR insiders buying or selling?
Recent insider activity shows net buying of $27.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.